Overview: AGA affects up to 96% of Caucasian men. This review recommends minoxidil, finasteride, and FDA-cleared HairMax LaserComb® for non-responders.

Key Findings:

• Topical minoxidil and finasteride are first-line treatments.
• HairMax LaserComb® is recommended for patients who do not respond to first-line modalities.

Source: PubMed ID: 24170634

Overview: 24-week, randomized, double-blind, sham device-controlled trial of LLLT for AGA. LLLT-treated scalp showed greater hair coverage and improvement.

Key Findings:

• LLLT-treated scalp showed significantly greater hair coverage and improvement in hair thickness, count, and coverage compared to sham.
• No serious adverse events were observed.

Source: PubMed ID: 29957664

Overview: Multicenter, randomized, sham device-controlled, double-blind study of HairMax LaserComb® for increasing terminal hair density in men and women.

Key Findings:

• LaserComb treatment significantly increased terminal hair density compared to sham.
• No serious adverse events; improvement was independent of age, sex, or device model.

Source: PubMed ID: 24474647

Overview: Review of fractional lasers and LLLT devices (HairMax LaserComb®) for hair regrowth in alopecia.

Key Findings:

• Fractional lasers may promote hair growth via wound healing; LLLT devices are safe and effective for hair loss.
• More randomized controlled trials are needed to establish optimal parameters and intervals.

Source: PubMed ID: 28812164